Spyre Therapeutics CEO Turtle Cameron disposes of 15,000 common shares worth $1.31 million
Reuters2026/09/04 01:33- Spyre Therapeutics CEO Turtle Cameron sold 15,000 common shares on Sep. 1, 2026 at weighted-average prices of USD 86.36 to USD 89.07.
- Cameron’s direct holding fell to 552,540 shares following the transactions.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Gold: Fed risk keeps bullion vulnerable – ING
Carlyle (CG.US) further expands energy business, acquires Parallax for 1 billion Canadian dollars
Carlyle's newly established company plans to acquire Parallax for approximately 1 billion Canadian dollars, continuing its expansion of light crude oil assets in Canada.
Bernstein: CoreWeave (CRWV.US) may be most affected if AI model development slows down
Bernstein stated that the calls from industry giants to slow down artificial intelligence (AI) model training could negatively impact data center developers and new cloud service providers, with CoreWeave possibly being one of the companies most affected.
Employment Data "Surprises" Support Bank of England to Hold Interest Rates Steady on Thursday
UK employers are laying off workers at the fastest pace in nine months, highlighting the weakness in the country's labor market.
Crypto prices
More
